ResearchInCh
China blood products industry is all along comparatively independent from global blood products industry. In the year of 1986, according to the rules from Ministry of Health, China prohibited the import of blood products except HAS. However, since 2002, HAS import had been also prohibited from BSE disease regions.
Considering the short supply of domestic blood products, in May 2008, State Council of China adjusted the import tariff of HSA products from 3% to zero during 1st Jun 2008 to the end of Dec 2008. However, due to the HAS price in China market lower than international market, foreign companies are seldom willing to export.
China has totally 33 blood products manufacturers. In the year of 2007, the blood products market scale in China was about CNY 6 billion. China has a great demand for albumin, due to the large number of liver disease patients; the other blood products also have a considerable demand in China such as gammaglobulin, immunoglobulin and plasma thromboplastin component.
Based on the authoritative statistics from General Administration of China Customs, Pharmaceutical Industry Association and National Bureau of Statistics, this report is focused on the actuality of China blood products industry, as well as its development trend and investment opportunities and risks.
Table of Contents
1. Overview of China Blood Products Industry
1.1 Market Overview
1.2 Key Manufacturers
2. China Blood Plasma Market
2.1 Blood Plasma Stations
2.2 Blood Plasma Production
2.3 Blood Plasma Price
3. Development of Global Blood Products Industry
3.1 Development Courses
3.2 Status Quo
4. Key Blood Products
4.1 HSA
4.2 IVIG
4.3 HBIG
4.4 Rabies Immunoglobulin
4.5 Tetanus Immunoglobulin
4.6 PTC
5. Key Manufacturers in China
5.1 Overview
5.2 Hualan Biological Engineering Co., Ltd
5.3 Shanghai RAAS Blood Products Co., Ltd
5.4 Shanghai Institute of Biological Products
5.5 Chengdu Rongsheng Pharmaceuticals Co., Ltd
5.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
5.7 Guiyang Qianfeng Biological Product Liability Co., Ltd.
6. Investment Analysis
6.1 Opportunities
6.2 Risks
6.3 Suggestions
Selected Charts
Market Structure of China Blood Products, 2007
Regional Sales of Top Six Blood Products Manufacturers in China, 2007
China Blood Products Industry Chain After the Reform of Blood Plasma Stations
Key Regulations of Blood Products in China
China Blood Plasma Productions, 2001-2007
China Blood Plasma Price and Forecast, 2005-2010
Blood Plasma Collection of Key Global Blood Products Manufacturers, 2007
Market Share Distribution of Global Key Blood Products Manufacturers, 2007
HAS Market Share Distribution of Hospitals in China, 2007
HAS Price Trend in China
China and Global HAS Consumption Per Capital
Sales Revenue of PTC in 16 Cities in China, 2001-2006
Major Products of Top Six Blood Products Manufacturers in China, 2007
Sales Revenue and Forecast of Hualan Biological Engineering Co., Ltd., 2007-2010
Profitability of Hualan Biological Engineering Co., Ltd &Shanghai RAAS Blood Products Co., Ltd
Major Products of Shanghai RAAS Blood Products Co., Ltd
Blood Plasma Collection and Production of Shanghai RAAS Blood Products Co., Ltd., 2005-2010
Sales Revenue and Forecast of Shanghai RAAS Blood Products Co., Ltd., 2005-2010
Fund-raising Investment Projects of of Shanghai RAAS Blood Products Co., Ltd., 2008
Blood Products of Shanghai Institute of Biological Products
Sales Network of Shanghai Institute of Biological Products, 2007
Sales Revenue, Net Profit and Forecast of Chengdu Rongsheng Pharmaceuticals Co., Ltd., 2008-2010
Sales Revenue of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., 2007
International Sales Network of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., 2007
The Highest Retail Price of Partial Blood Products according to National Development and Reform Commission.
For details of this report please visit http://www.researchinchina.com/
Photo:
http://www.prlog.org/
